Horizon Investments LLC Buys 92 Shares of Humana Inc. $HUM

Horizon Investments LLC increased its stake in Humana Inc. (NYSE:HUM) by 4.7% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,039 shares of the insurance provider’s stock after purchasing an additional 92 shares during the quarter. Horizon Investments LLC’s holdings in Humana were worth $540,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in Humana by 8.9% in the 1st quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider’s stock worth $3,697,222,000 after purchasing an additional 1,143,662 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Humana by 40,881.1% in the first quarter. GAMMA Investing LLC now owns 781,099 shares of the insurance provider’s stock worth $2,066,790,000 after buying an additional 779,193 shares in the last quarter. Southpoint Capital Advisors LP bought a new position in shares of Humana in the fourth quarter valued at approximately $190,282,000. Nuveen LLC purchased a new position in Humana during the first quarter valued at approximately $171,220,000. Finally, 8 Knots Management LLC purchased a new position in Humana during the fourth quarter valued at approximately $145,258,000. 92.38% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

HUM has been the topic of several recent analyst reports. Morgan Stanley lowered their target price on shares of Humana from $290.00 to $277.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 31st. Wall Street Zen downgraded Humana from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Oppenheimer lifted their price objective on Humana from $300.00 to $310.00 and gave the company an “outperform” rating in a research note on Thursday, May 1st. Wells Fargo & Company decreased their target price on Humana from $348.00 to $344.00 and set an “overweight” rating on the stock in a research note on Thursday. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $290.00 price target on shares of Humana in a research report on Thursday, May 1st. Seventeen equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $281.43.

Humana Stock Performance

Shares of HUM opened at $286.73 on Monday. Humana Inc. has a one year low of $206.87 and a one year high of $382.72. The company has a 50-day simple moving average of $242.70 and a two-hundred day simple moving average of $253.24. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. The firm has a market capitalization of $34.49 billion, a PE ratio of 22.01, a price-to-earnings-growth ratio of 1.68 and a beta of 0.44.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing the consensus estimate of $6.32 by ($0.05). The firm had revenue of $32.39 billion for the quarter, compared to the consensus estimate of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.96 earnings per share. On average, analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.